Founder’s Vision
ANKTIVA
BCG
Our Science
Careers
Contact
Patients & Caregivers
ANKTIVA®
Clinical Trials
Patients
Therapeutic Areas
Bladder Cancer
Glioblastoma
HIV
Human Papillomavirus
Lymphopenia
Lynch Syndrome
Non-Hodgkin Lymphoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Healthcare Providers
ANKTIVA®
Clinical Trials
Trial Investigators
Expanded Access
Researchers
Platforms & Modalities
Trial Investigators
Cell Licensing
Publications
Our Company
About
Pipeline
Contact
Compliance & Transparency
News and Events
Investors
Select Page
Acceptance Requirements
Adult patients diagnosed with histologically-confirmed glioblastoma that has progressed after initial therapy or therapies
Must have previous first line treatment with at least radiotherapy and temozolomide.
Search for:
Recent Posts
LUGPA Regional Meeting
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
Jefferies Global Healthcare Conference 2025
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield
TM
Platform in the Middle East